178 related articles for article (PubMed ID: 17416342)
1. The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.
Chuu CP; Chen RY; Hiipakka RA; Kokontis JM; Warner KV; Xiang J; Liao S
Biochem Biophys Res Commun; 2007 Jun; 357(2):341-6. PubMed ID: 17416342
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.
Chuu CP; Hiipakka RA; Kokontis JM; Fukuchi J; Chen RY; Liao S
Cancer Res; 2006 Jul; 66(13):6482-6. PubMed ID: 16818617
[TBL] [Abstract][Full Text] [Related]
3. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.
Fukuchi J; Kokontis JM; Hiipakka RA; Chuu CP; Liao S
Cancer Res; 2004 Nov; 64(21):7686-9. PubMed ID: 15520170
[TBL] [Abstract][Full Text] [Related]
5. Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells.
Trasino SE; Kim YS; Wang TT
Mol Cancer Ther; 2009 Jul; 8(7):1934-45. PubMed ID: 19531574
[TBL] [Abstract][Full Text] [Related]
6. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice.
Liu Y; Yan C; Wang Y; Nakagawa Y; Nerio N; Anghel A; Lutfy K; Friedman TC
Endocrinology; 2006 Nov; 147(11):5061-8. PubMed ID: 16873540
[TBL] [Abstract][Full Text] [Related]
7. T0901317 is a dual LXR/FXR agonist.
Houck KA; Borchert KM; Hepler CD; Thomas JS; Bramlett KS; Michael LF; Burris TP
Mol Genet Metab; 2004; 83(1-2):184-7. PubMed ID: 15464433
[TBL] [Abstract][Full Text] [Related]
8. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
9. Lycopene and the LXRα agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARγ-LXRα-ABCA1 pathway.
Yang CM; Lu YL; Chen HY; Hu ML
J Nutr Biochem; 2012 Sep; 23(9):1155-62. PubMed ID: 22137263
[TBL] [Abstract][Full Text] [Related]
10. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
11. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
[TBL] [Abstract][Full Text] [Related]
12. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro.
Zhang X; Zhu Z; Luo G; Zheng L; Nilsson-Ehle P; Xu N
Biochem Biophys Res Commun; 2008 Jun; 371(1):114-7. PubMed ID: 18413148
[TBL] [Abstract][Full Text] [Related]
13. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation by activating the liver X receptor.
Lee JH; Gong H; Khadem S; Lu Y; Gao X; Li S; Zhang J; Xie W
Endocrinology; 2008 Aug; 149(8):3778-88. PubMed ID: 18450964
[TBL] [Abstract][Full Text] [Related]
15. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.
Blaschke F; Takata Y; Caglayan E; Collins A; Tontonoz P; Hsueh WA; Tangirala RK
Circ Res; 2006 Dec; 99(12):e88-99. PubMed ID: 17110595
[TBL] [Abstract][Full Text] [Related]
16. Modulation of liver X receptor signaling as novel therapy for prostate cancer.
Chuu CP; Kokontis JM; Hiipakka RA; Liao S
J Biomed Sci; 2007 Sep; 14(5):543-53. PubMed ID: 17372849
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
18. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells.
Wente W; Brenner MB; Zitzer H; Gromada J; Efanov AM
Endocrinology; 2007 Apr; 148(4):1843-9. PubMed ID: 17194744
[TBL] [Abstract][Full Text] [Related]
19. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.
Stan SD; Singh SV
Clin Cancer Res; 2009 Aug; 15(15):4895-903. PubMed ID: 19622577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
